Showing 2471-2480 of 5693 results for "".
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- The Children’s Eye Foundation of AAPOS Debuts “THE CURIOUS EYE” Interactive Storybookhttps://modernod.com/news/the-childrens-eye-foundation-of-aapos-debuts-the-curious-eye-interactive-storybook/2479230/The Children’s Eye Foundation of AAPOS unveiled the world’s first interactive children’s book to help screen for color vision deficiency (CVD), commonly known as color blindness. The foundation has posted a free digital version of THE CURIOUS EYE at
- Essilor Receives FDA Breakthrough Device Designation for Essilor Stellest Spectacle Lenshttps://modernod.com/news/essilor-receives-fda-breakthrough-device-designation-for-essilor-stellest-specticle-lens/2479220/Essilor announced that the FDA has granted Breakthrough Device designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- NUST MISIS Scientists Say They Developed a Safe Drug to Treat Eye Inflammationhttps://modernod.com/news/nust-misis-scientists-say-they-developed-a-safe-drug-to-treat-eye-inflammation/2479203/A Russian-American research team from The National University of Science and Technology MISIS has presented a new therapeutic method using nanoparticles of an antioxidant enzyme, developed specifically for the eyes. It relieves inflammation and repairs tissue without causing side effects: irritat
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- Tarsus Pharmaceuticals Presents Results of Atlas Study Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/Tarsus Pharmaceuticals announced data from its Demodex blepharitis clinical program presented at the virtual Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. Tarsus’ lead product candidate, TP-03, is a topical ophthalmic formulation of lotilaner, a well-characteriz
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (